National Health Mission, Madhya Pradesh and Sanofi India sign MoU to strengthen public health service

IMT News Desk
IMT News Desk
· 3 min read
NHM MP strengthens healthcare access through Mobile Medical Units offering free diagnostics, NCD screening, and tele-consultations in remote areas.

The National Health Mission Madhya Pradesh (NHM, MP) signed a Memorandum of Understanding (MoU) with Sanofi (India) to strengthen public health services within the state.

The objective of this partnership is to raise awareness of Non-Communicable Diseases (NCDs), such as diabetes, to encourage early detection and treatment, and to provide support to people living with rare diseases.

Dr. Saloni Sidana (IAS), Mission Director, NHM MP, stated that this initiative would strengthen access to healthcare services across the state, particularly in remote and underserved regions. Through Mobile Medical Units, people will have access to free diagnostics, treatment, and tele-consultations with doctors within their own localities. She noted that awareness campaigns, early risk detection, and referral services for diabetes and other NCDs would be bolstered. Furthermore, mechanisms for early detection, free screening, and improved treatment of rare diseases will be developed to ensure that patients receive timely and appropriate care. She further emphasized that imparting accurate information regarding health, nutrition and lifestyle to children at the school level is of paramount importance, for children not only adopt healthy habits themselves but also spread awareness within their families and communities.

Deepak Arora (Managing Director of Sanofi India Limited) highlighted the critical need for the early detection of rising NCDs in India. He affirmed that Sanofi remains committed to such partnerships to empower the healthcare system and ensure better health outcomes for patients.

Signed by Dr. Saloni Sidana, Mission Director, National Health Mission, Madhya Pradesh, and Mr. Deepak Arora, Managing Director, Sanofi India Limited, this initiative is based on collaboration across key areas to improve the accessibility and quality of healthcare services in Madhya Pradesh. Under this agreement, work will be undertaken in the following key areas:

• Rare Diseases: This partnership will strengthen the infrastructure for the diagnosis and treatment of rare diseases. This includes training for healthcare professionals, improving early detection through advanced technologies, and arranging for free screening for selected rare diseases at designated institutions.

• Diabetes and NCD Awareness: Early risk identification, awareness campaigns, and referral services for diabetes and other non-communicable diseases will be conducted. Technical support will be provided across the entire state to facilitate this effort.

• School Health Program: Through programs such as “Kids and Diabetes in Schools (KiDS),” students, teachers, and parents/guardians will be sensitized on healthy lifestyles and disease prevention.

• Capacity Building: Structured training programs and technical sessions will be organized to facilitate the training and skill enhancement of doctors, nurses, paramedical staff, and community health workers.

• Mobile Medical Units (MMUs): Mobile Medical Units will be deployed in selected districts like Singrauli, Balaghat, and Anuppur, to extend healthcare services to underserved communities. These units will provide free screening and treatment for conditions such as diabetes, hypertension, and oral cancer. Each unit will be staffed by trained healthcare professionals and will also provide tele-consultation facilities with doctors. Initially, this service will be launched in the districts of Singrauli, Balaghat, and Anuppur, and will subsequently be expanded to other districts on a need basis.

This partnership reflects a strong commitment toward providing affordable, accessible, and high-quality healthcare services to all sections of society.

Read Next

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya
News
June 5, 2026

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya

Union Health Minister J P Nadda on Thursday declared that the Central Government remains firmly committed to strengthening healthcare infrastructure across the Northeast and ensuring that advanced medical services reach people living in remote and underserved areas of the region. Nadda made these remarks while inaugurating ARHI Hospital in Meghalaya’s Ri-Bhoi district- a new super-specialty […]
Article by: IMT News Desk
Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today
News
June 5, 2026

Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today

Mumbai-based Hexagon Nutrition Ltd has mobilised Rs 41.66 crore from anchor investors ahead of its initial public offering (IPO), which opened for public subscription on June 5 and will remain open until June 9, 2026. According to a circular uploaded on BSE’s website, the company allotted a total of 92.57 lakh equity shares to anchor […]
Article by: IMT News Desk
Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval
News
June 5, 2026

Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval

Otsuka Pharmaceutical has reported that its approved kidney disease drug Voyxact (sibeprenlimab) preserved kidney function over 12 months in a late-stage clinical study, marking a significant milestone in the treatment of immunoglobulin A nephropathy (IgAN), a serious autoimmune condition that progressively damages the kidneys. In the Phase 3 VISIONARY trial involving 320 participants, patients who […]
Article by: IMT News Desk
Akums Receives European CEP Approval for Cefpodoxime Proxetil
News
June 4, 2026

Akums Receives European CEP Approval for Cefpodoxime Proxetil

Akums Drugs & Pharmaceuticals Ltd. has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its active pharmaceutical ingredient (API), Cefpodoxime Proxetil. The CEP certification confirms that Akums’ manufacturing process and quality standards for Cefpodoxime Proxetil comply with the requirements of the European Pharmacopoeia. The […]
Article by: IMT News Desk